Risankizumab,Ixekizumab,Secukinumab
abbvie,eli lilly,novartis,Boehringer Ingelheim
['risan', 'ixekizumab', 'psoriasis', 'secukinumab', 'derm']
new data presented at #aad2023 indicates that patients with #psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor. check out the data here: #aad23 #dermatology #plaquepsoriasis
Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.